Actively Recruiting
A Study of HDM2005 in Patients With Advanced Solid Tumor
Led by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Updated on 2025-06-08
72
Participants Needed
1
Research Sites
130 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a study evaluating the efficacy, safety, and pharmacokinetics ofHDM2005 in participants with metastatic solid tumors.
CONDITIONS
Official Title
A Study of HDM2005 in Patients With Advanced Solid Tumor
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Agree to follow the study protocol and voluntarily sign consent
- Male or female aged 18 years or older
- ECOG performance status of 0-1
- Life expectancy of at least 3 months
- Confirmed advanced solid tumors by tissue examination
- Metastatic disease progressed after prior appropriate treatment
- Provide archived or fresh tissue for ROR1 expression testing
- Radiographically measurable disease present
- Recovered to Grade 1 or less from any prior anticancer therapy side effects
- Adequate organ function
- Female participants of childbearing potential must use contraception and have a negative pregnancy test; males must agree to contraception during and 6 months after the study
You will not qualify if you...
- Active brain metastases (unstable, symptomatic, or requiring certain medications)
- Another primary cancer except treated non-melanoma skin cancer or carcinoma in situ without recurrence
- History of severe bleeding disorders
- History of pancreatitis within 6 months
- History or evidence of active interstitial lung disease or radiation pneumonitis
- Uncontrolled pleural, pericardial effusion, or ascites needing repeated drainage
- Prior solid organ transplant
- Peripheral neuropathy greater than Grade 1
- Significant cardiovascular or cerebrovascular disease
- Uncontrolled infection
- Active infectious diseases like HIV, active hepatitis B or C, or active syphilis
- Receiving corticosteroids above a certain dose
- Contraindication to any HDM2005 components
- History of severe allergic reactions or uncontrolled asthma or COPD
- Pregnant, lactating, or planning pregnancy during study
- Mental illness or substance abuse impacting study cooperation
- Any medical condition or treatment that might affect study outcomes or safety as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
J
Jun Zhou
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here